Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 112
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT04091204 | Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study | ||
| NCT06341764 | Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma | ||
| NCT01628211 | Second Look Laparoscopy in Colorectal Cancer | ||
| NCT07213570 | STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer | ||
| NCT01644825 | Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer | ||
| NCT04893785 | A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM) | ||
| NCT04290299 | Endometrial Cancer Conservative Treatment (E.C.Co). A Multicentre Archive | ||
| NCT02408536 | Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian Cancer | ||
| NCT06270602 | The ONCOCAMP Study | ||
| NCT06893861 | Assessment of the Effectiveness of the Metabolomic Approach in Screening for Endometrial Cancer | ||
| NCT05818020 | Multidisciplinary Integrated Platform for a Technological Innvovative Approach to Oncotherapies | ||
| NCT04397601 | Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal Cancer | ||
| NCT00349219 | TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer | ||
| NCT05821556 | Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients | ||
| NCT01359956 | Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma | ||
| NCT04425239 | Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer | ||
| NCT06886282 | Spatial RadiomIcs and TRanscriptomics to the DIscovery of the Cross-link Between Colon Cancer and ChrOnic Kidney Disease | ||
| NCT01593488 | Liposomal Cytarabine in the Treatment of Central Nervous System Resistant or Relapsed Acute Lymphoblastic Leukemia in Children | ||
| NCT03410784 | Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer | ||
| NCT02069067 | Observational Study of Incidence of Breakthrough Cancer Pain and How it is Treated | ||
| NCT04893356 | Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT) | ||
| NCT06880523 | STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma | ||
| NCT00996983 | Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer | ||
| NCT06218511 | A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1) | ||
| NCT03874026 | Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients | ||
| NCT05817227 | Selenoproteins as Prognostic Markers and Therapeutic Targets in Breast Cancer. | ||
| NCT05733793 | Molecular Data and Their Correlations With Clinical Outcomes in Gynecological Cancer Patients. | ||
| NCT04726228 | Pain ASsessment in CAncer Patients by Machine LEarning (PASCALE) | ||
| NCT00401635 | END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin | ||
| NCT00345059 | The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer | ||
| NCT01005641 | ELBA: Exemestane and Lapatinib in Advanced Breast Cancer | ||
| NCT00401674 | MITO-5: Weekly Carboplatin and Paclitaxel as First Line Chemotherapy for Elderly Patients With Ovarian Cancer | ||
| NCT04122911 | Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas | ||
| NCT02273375 | Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC | ||
| NCT00434031 | CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer | ||
| NCT02786875 | Diet, Exercise and Vitamin D in Breast Cancer Recurrence | ||
| NCT06714357 | ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer | ||
| NCT03975114 | A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5) | ||
| NCT02619435 | Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer | ||
| NCT00401427 | HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer | ||
| NCT07267780 | Contribution of Oncovascular Surgery in the Treatment of Gynecological Advanced Malignant Diseases. | ||
| NCT06905145 | Molecular-Based Selection of Patients with Head and Neck Squamous Cell Carcinoma: Biomarker Analysis | ||
| NCT04071704 | Assessing Health-related Quality of Life in Sarcoma Patients | ||
| NCT06032975 | PRO for Fighting FT in Ovarian Cancer | ||
| NCT06236464 | Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas | ||
| NCT00403429 | MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer | ||
| NCT05818865 | "Principle Test" for Isolation and Characterization of Circulating Cancer Cells (CTC)-CXCR4+. | ||
| NCT00326456 | MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer | ||
| NCT03503786 | Carboplatin, Paclitaxel With or Without Avelumab in Advanced or Recurrent Endometrial Cancer | ||
| NCT02784171 | Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma |
